Merus (MRUS) Expected to Announce Quarterly Earnings on Wednesday

Merus (NASDAQ:MRUS) is expected to issue its quarterly earnings data before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.89) per share and revenue of $10.57 million for the quarter.

Merus Stock Performance

MRUS stock opened at $47.37 on Monday. Merus has a one year low of $37.77 and a one year high of $61.61. The firm has a market cap of $3.24 billion, a PE ratio of -11.99 and a beta of 1.11. The firm’s 50 day moving average price is $41.72 and its 200-day moving average price is $46.91.

Wall Street Analyst Weigh In

Several brokerages have recently commented on MRUS. Needham & Company LLC reaffirmed a “buy” rating and issued a $85.00 price target on shares of Merus in a research note on Monday, December 9th. HC Wainwright reaffirmed a “buy” rating and issued a $85.00 target price on shares of Merus in a research report on Monday, December 2nd. Guggenheim reiterated a “buy” rating on shares of Merus in a research report on Wednesday, February 12th. Wells Fargo & Company started coverage on shares of Merus in a report on Friday, February 7th. They issued an “overweight” rating and a $91.00 price objective on the stock. Finally, The Goldman Sachs Group assumed coverage on shares of Merus in a report on Thursday, November 21st. They issued a “buy” rating and a $73.00 target price for the company. One analyst has rated the stock with a sell rating, fourteen have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $85.92.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.